Variability of Ha-ras (codon 12) proto-oncogene mutations in diverse thyroid cancers

被引:18
作者
Bouras, M
Bertholon, J
Dutrieux-Berger, N
Parvaz, P
Paulin, C
Revol, A
机构
[1] Ctr Hosp Lyon Sud, Lab Biol Mol & Pediat, F-69475 Pierre Benite, France
[2] Hop Hotel Dieu, Lab Anatopathol, F-69288 Lyon, France
[3] Ctr Hosp Lyon Sud, Lab Cytol, F-69475 Pierre Benite, France
[4] Fac Pharm Lyon, Lab Biochim Endocrinienne & Mol, Inst Sci Pharmaceut & Biol, F-69373 Lyon 08, France
关键词
D O I
10.1530/eje.0.1390209
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Structural alterations to proto-oncogene sequences may be involved in the pathogenesis of human thyroid neoplasms. We studied 128 thyroid tumours (35 benign and 93 malignant) for las gene point mutations in three different codons (12, 13 and 61) using a restriction fragment length polymorphism technique and direct sequencing of double-stranded DMA on polymerase chain-reaction-amplified tumour DNA. We found a high frequency of ras mutation for the Ha-ras codon 12 in follicular adenomas (7 of 35), particularly in atypical adenomas (5 of 17), in follicular carcinomas (6 of 19), with a high percentage for Hurthle cell carcinomas (6 of 11), and in papillary carcinomas (4 of 66), Point mutations for other ras genes in different codons studied were weak to absent. No mutation was found in undifferentiated carcinomas (n = 8). The predominant amino acid substitution both in the adenomas and in the differentiated rumours was glycine to valine (GGC to GTC) at position 12 of the Ha-ras gene. Our results obtained on a large series confirm the frequent occurrence of Ha-ras codon 12 gene mutations both in adenomas and in carcinomas. The frequency of ras mutations is linked to the geographical origin of the population studied, and varies (0-85%) from one cancer type to another according to published data. Therefore, these mutations are merely an expression of cellular transformation.
引用
收藏
页码:209 / 216
页数:8
相关论文
共 33 条
[1]   RAS GENES [J].
BARBACID, M .
ANNUAL REVIEW OF BIOCHEMISTRY, 1987, 56 :779-827
[2]  
Bohle RM, 1996, AM J PATHOL, V148, P731
[3]  
BOS JL, 1989, CANCER RES, V49, P4682
[4]  
BOULTWOOD J, 1988, CANCER RES, V48, P4073
[5]  
CHALLETON C, 1995, ONCOGENE, V11, P601
[6]  
DOCKHORNDWORNICZAK B, 1990, VERH DEUT G, V74, P415
[7]   ROLE OF RAS AND GSP ONCOGENES IN HUMAN EPITHELIAL THYROID TUMORIGENESIS [J].
DUVILLARD, JA ;
SCHLUMBERGER, M ;
WICKER, R ;
CAILLOU, B ;
ROCHEFORT, P ;
FEUNTEUN, J ;
MONIER, R ;
PARMENTIER, C ;
SUAREZ, HG .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1995, 18 (02) :124-126
[8]   MUTATIONAL ACTIVATION OF RAS AND GSP ONCOGENES IN DIFFERENTIATED THYROID-CANCER AND THEIR BIOLOGICAL IMPLICATIONS [J].
GORETZKI, PE ;
LYONS, J ;
STACYPHIPPS, S ;
ROSENAU, W ;
DEMEURE, M ;
CLARK, OH ;
MCCORMICK, F ;
ROHER, HD ;
BOURNE, HR .
WORLD JOURNAL OF SURGERY, 1992, 16 (04) :576-582
[9]  
HEDINGER CH, 1989, INT HISTOLOGICAL CLA
[10]  
JIANG W, 1989, ONCOGENE, V4, P923